@article{fdi:010040959, title = {{E}fficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in {C}asamance, southern {S}enegal - art. no. 150}, author = {{B}rasseur, {P}hilippe and {A}gnamey, {P}. and {G}aye, {O}. and {V}aillant, {M}. and {T}aylor, {W}. {R}. {J}. and {O}lliaro, {P}. {L}.}, editor = {}, language = {{ENG}}, abstract = {{B}ackground: {T}here are no data on the long term use of an artemisinin combination treatment in moderate or high transmission areas of {A}frica. {M}ethods and findings: {A}rtesunate plus amodiaquine ({AS}+{AQ}) was used to treat slide-proven {P}lasmodium falciparum-infected patients of all ages in the {O}ussouye district, {C}asamance, {S}enegal, over a period of six years (2000 to 2005). {E}fficacy, by {K}aplan {M}eier survival analysis (n = 966), and safety (adverse event rates, n = 752) were determined over 28 days. {A} weight-based dosing regimen was used for the loose tablets during 2000-2003 (n = 731) and a commercially available co-blister was used during 2004-2005 (n = 235). {A}nnual crude (non {PCR} corrected) rates remained stable over the study period [range 88.5-96.7%; overall 94.6 (95% {CI} 92.9-95.9)]. {N}ine co-blister treated patients (0.9%) withdrew because of drug-related adverse events; seven had gastrointestinal complaints of whom two were hospitalized for vomiting. {B}y {D}ay 28, the mean total bilirubin (n = 72), {AST} (n = 94) and {ALT} (n = 95) values decreased. {T}hree patients had {D}ay 28 {AST}/{ALT} values > 40 < 200 {IU}/{L}. {C}hanges in white cell counts were unremarkable (n = 87). {C}onclusion: {AS}+{AQ} in combination was highly efficacious and well-tolerated in this area and justifies the decision to use it as first line treatment. {L}ong-term monitoring of safety and efficacy should continue.}, keywords = {}, booktitle = {}, journal = {{M}alaria {J}ournal}, volume = {6}, numero = {}, pages = {{NIL}_1--{NIL}_11}, ISSN = {1475-2875}, year = {2007}, DOI = {10.1186/1475-2875-6-150}, URL = {https://www.documentation.ird.fr/hor/fdi:010040959}, }